Scott E Wenderfer1, Joyce C Chang2, Amy Goodwin Davies3, Ingrid Y Luna3, Rebecca Scobell4,3, Cora Sears2, Bliss Magella5, Mark Mitsnefes5,6, Brian R Stotter7, Vikas R Dharnidharka7, Katherine D Nowicki8, Bradley P Dixon9, Megan Kelton10,11, Joseph T Flynn10,11, Caroline Gluck12, Mahmoud Kallash13,14, William E Smoyer13,14, Andrea Knight15, Sangeeta Sule16, Hanieh Razzaghi3, L Charles Bailey3,17, Susan L Furth17,18, Christopher B Forrest3,17, Michelle R Denburg17,18,19, Meredith A Atkinson20. 1. Pediatric Nephrology, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas wenderfe@bcm.edu. 2. Pediatric Rheumatology, Perelman School of Medicine at the University of Pennsylvania, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 3. Applied Clinical Research Center, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 4. Pediatric Nephrology, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas. 5. Pediatric Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 6. Pediatrics, University of Cincinnati, Cincinnati, Ohio. 7. Pediatric Nephrology, Hypertension and Pheresis, St. Louis Children's Hospital, Washington University in St. Louis, St. Louis, Missouri. 8. Pediatric Rheumatology, University of Colorado School of Medicine, Aurora, Colorado. 9. Pediatric Nephrology, University of Colorado School of Medicine, Aurora, Colorado. 10. Pediatrics, University of Washington, Seattle, Washington. 11. Nephrology, Seattle Children's Hospital, Seattle, Washington. 12. Pediatric Nephrology, Nemours/Alfred I. DuPont Hospital for Children, Wilmington, Delaware. 13. Center for Clinical and Translational Research, Nationwide Children's Hospital, Columbus, Ohio. 14. Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio. 15. Pediatric Rheumatology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 16. Pediatric Rheumatology, George Washington University, Children's National Medical Center, Washington, DC. 17. Pediatrics, Perelman School of Medicine at the University of Pennsylvania, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 18. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 19. Center for Pediatric Clinical Effectiveness, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 20. Pediatric Nephrology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND AND OBJECTIVES: Performing adequately powered clinical trials in pediatric diseases, such as SLE, is challenging. Improved recruitment strategies are needed for identifying patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Electronic health record algorithms were developed and tested to identify children with SLE both with and without lupus nephritis. We used single-center electronic health record data to develop computable phenotypes composed of diagnosis, medication, procedure, and utilization codes. These were evaluated iteratively against a manually assembled database of patients with SLE. The highest-performing phenotypes were then evaluated across institutions in PEDSnet, a national health care systems network of >6.7 million children. Reviewers blinded to case status used standardized forms to review random samples of cases (n=350) and noncases (n=350). RESULTS: Final algorithms consisted of both utilization and diagnostic criteria. For both, utilization criteria included two or more in-person visits with nephrology or rheumatology and ≥60 days follow-up. SLE diagnostic criteria included absence of neonatal lupus, one or more hydroxychloroquine exposures, and either three or more qualifying diagnosis codes separated by ≥30 days or one or more diagnosis codes and one or more kidney biopsy procedure codes. Sensitivity was 100% (95% confidence interval [95% CI], 99 to 100), specificity was 92% (95% CI, 88 to 94), positive predictive value was 91% (95% CI, 87 to 94), and negative predictive value was 100% (95% CI, 99 to 100). Lupus nephritis diagnostic criteria included either three or more qualifying lupus nephritis diagnosis codes (or SLE codes on the same day as glomerular/kidney codes) separated by ≥30 days or one or more SLE diagnosis codes and one or more kidney biopsy procedure codes. Sensitivity was 90% (95% CI, 85 to 94), specificity was 93% (95% CI, 89 to 97), positive predictive value was 94% (95% CI, 89 to 97), and negative predictive value was 90% (95% CI, 84 to 94). Algorithms identified 1508 children with SLE at PEDSnet institutions (537 with lupus nephritis), 809 of whom were seen in the past 12 months. CONCLUSIONS: Electronic health record-based algorithms for SLE and lupus nephritis demonstrated excellent classification accuracy across PEDSnet institutions.
BACKGROUND AND OBJECTIVES: Performing adequately powered clinical trials in pediatric diseases, such as SLE, is challenging. Improved recruitment strategies are needed for identifying patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Electronic health record algorithms were developed and tested to identify children with SLE both with and without lupus nephritis. We used single-center electronic health record data to develop computable phenotypes composed of diagnosis, medication, procedure, and utilization codes. These were evaluated iteratively against a manually assembled database of patients with SLE. The highest-performing phenotypes were then evaluated across institutions in PEDSnet, a national health care systems network of >6.7 million children. Reviewers blinded to case status used standardized forms to review random samples of cases (n=350) and noncases (n=350). RESULTS: Final algorithms consisted of both utilization and diagnostic criteria. For both, utilization criteria included two or more in-person visits with nephrology or rheumatology and ≥60 days follow-up. SLE diagnostic criteria included absence of neonatal lupus, one or more hydroxychloroquine exposures, and either three or more qualifying diagnosis codes separated by ≥30 days or one or more diagnosis codes and one or more kidney biopsy procedure codes. Sensitivity was 100% (95% confidence interval [95% CI], 99 to 100), specificity was 92% (95% CI, 88 to 94), positive predictive value was 91% (95% CI, 87 to 94), and negative predictive value was 100% (95% CI, 99 to 100). Lupus nephritis diagnostic criteria included either three or more qualifying lupus nephritis diagnosis codes (or SLE codes on the same day as glomerular/kidney codes) separated by ≥30 days or one or more SLE diagnosis codes and one or more kidney biopsy procedure codes. Sensitivity was 90% (95% CI, 85 to 94), specificity was 93% (95% CI, 89 to 97), positive predictive value was 94% (95% CI, 89 to 97), and negative predictive value was 90% (95% CI, 84 to 94). Algorithms identified 1508 children with SLE at PEDSnet institutions (537 with lupus nephritis), 809 of whom were seen in the past 12 months. CONCLUSIONS: Electronic health record-based algorithms for SLE and lupus nephritis demonstrated excellent classification accuracy across PEDSnet institutions.
Authors: Joyce C Chang; Brian R White; Matthew D Elias; Rui Xiao; Andrea M Knight; Pamela F Weiss; Laura Mercer-Rosa Journal: Pediatr Cardiol Date: 2019-04-30 Impact factor: 1.655
Authors: Michelle R Denburg; Hanieh Razzaghi; L Charles Bailey; Danielle E Soranno; Ari H Pollack; Vikas R Dharnidharka; Mark M Mitsnefes; William E Smoyer; Michael J G Somers; Joshua J Zaritsky; Joseph T Flynn; Donna J Claes; Bradley P Dixon; Maryjane Benton; Laura H Mariani; Christopher B Forrest; Susan L Furth Journal: J Am Soc Nephrol Date: 2019-11-15 Impact factor: 10.121
Authors: William A Primack; Kevin E Meyers; Suzanne J Kirkwood; Holly S Ruch-Ross; Carrie L Radabaugh; Larry A Greenbaum Journal: Am J Kidney Dis Date: 2015-04-22 Impact factor: 8.860
Authors: Scott E Wenderfer; Jerome C Lane; Ibrahim F Shatat; Emily von Scheven; Natasha M Ruth Journal: Pediatr Rheumatol Online J Date: 2015-06-19 Impact factor: 3.054
Authors: Christopher B Forrest; Peter A Margolis; L Charles Bailey; Keith Marsolo; Mark A Del Beccaro; Jonathan A Finkelstein; David E Milov; Veronica J Vieland; Bryan A Wolf; Feliciano B Yu; Michael G Kahn Journal: J Am Med Inform Assoc Date: 2014-05-12 Impact factor: 4.497
Authors: Pooja Patel; Marietta de Guzman; M John Hicks; Joseph G Maliakkal; Michelle N Rheault; David T Selewski; Katherine Twombley; Jason M Misurac; Cheryl L Tran; Alexandru R Constantinescu; Ali M Onder; Meredith Seamon; Wacharee Seeherunvong; Vaishali Singh; Cynthia Pan; Daryl M Okamura; Abiodun Omoloja; Mahmoud Kallash; William E Smoyer; Guillermo Hidalgo; Scott E Wenderfer Journal: Pediatr Nephrol Date: 2022-03-28 Impact factor: 3.651
Authors: Brian R Stotter; Ellen Cody; Hongjie Gu; Ankana Daga; Larry A Greenbaum; Minh Dien Duong; Alexandra Mazo; Beatrice Goilav; Alexis Boneparth; Mahmoud Kallash; Ahmed Zeid; Wacharee Seeherunvong; Rebecca R Scobell; Issa Alhamoud; Caitlin E Carter; Siddharth Shah; Caroline E Straatmann; Bradley P Dixon; Jennifer C Cooper; Raoul D Nelson; Deborah M Levy; Hermine I Brunner; Priya S Verghese; Scott E Wenderfer Journal: Pediatr Nephrol Date: 2022-10-17 Impact factor: 3.651
Authors: Samar A Soliman; Anam Haque; Kamala Vanarsa; Ting Zhang; Faten Ismail; Kyung Hyun Lee; Claudia Pedroza; Larry A Greenbaum; Sherene Mason; M John Hicks; Scott E Wenderfer; Chandra Mohan Journal: Front Immunol Date: 2022-05-26 Impact factor: 8.786